Skip to content

Study to assess changes in walking, balance, and muscle stiffness before and after a nerve block procedure in patients with hip adductor spasticity

Clinical, gait and balance parameters after diagnostic obturator nerve block in patients with spasticity - a pre-post interventional study - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096120
Enrollment
15
Registered
2025-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I639- Cerebral infarction, unspecified Health Condition 2: G809- Cerebral palsy, unspecified Health Condition 3: G35- Multiple sclerosis Health Condition 4: S141- Other and unspecified injuries ofcervical spinal cord Health Condition 5: S241- Other and unspecified injuries ofthoracic spinal cord Health Condition 6: S341- Other and unspecified injury of lumbar and sacral spinal cord Health Condition 7: S069- Unspecified intracranial injury

Interventions

Intervention1: USG guided diagnostic Obturator nerve block: Patient monitor will be connected to the patient for assessment of heart rate, SpO2, respiratory rate, blood pressure and temperature throug

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged greater than or equal to 18 years 2. Patients affected by hip adductor spasticity (unilateral or bilateral) because of underlying generalised or focal cerebral and spinal pathologies like cerebrovascular accident, spinal cord injury, traumatic brain injury, cerebral palsy or multiple sclerosis. 3. Hip adductor spasticity severity 1, 1 plus, 2 or 3 on the Modified Ashworth Scale (MAS) 4. Use of any anti-spasticity medications at stable doses for at least 1 month prior to enrolment, and the participant must agree to maintain same dose throughout the study

Exclusion criteria

Exclusion criteria: 1. Patients who do not wish to be included in the study 2. Patients who have an allergy to lidocaine 3. Hip adductor spasticity severity 4 on the Modified Ashworth Scale (MAS) 4. Established severe contracture of the hip adductors. 5. Received recent treatment with botulinum toxin (within 6 months), phenol injection (within 24 months). 6. Unstable medical conditions such as peripheral vascular disease, hepatic disease, renal disease, coronary artery disease, malignant hyperthermia and an estimated survival of less than 6 months. 7. Patients with a history of dystonic posture or deep vein thrombosis in the lower limbs 8. Pregnant women

Design outcomes

Primary

MeasureTime frame
a) Modified Ashworth Scale (MAS) b) Spasm Frequency Scale c) R1 of Modified Tardieu Scale (both in knee flexed and extended condition).Timepoint: Baseline, 30 minutes after procedure

Secondary

MeasureTime frame
a) Gait parameters: 1. Step length, Swing time (SwT), Stance time (StT), Single-leg support time (SLST), Double-leg support time (DLST) and Step Length Symmetry Ratio 2. Walking velocityTimepoint: Baseline, 30 minutes after procedure;b) Balance parameters: 1. Postural stability test 2. Fall risk test 3. Limits of stability testTimepoint: Baseline, 30 minutes after procedure

Countries

India

Contacts

Public ContactJaydeep Nandi

AIIMS Raipur

jaydeepnandidgp@gmail.com9760456198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026